BioInvent International AB celebró un evento con líderes de opinión clave el 27 de mayo de 2026 para debatir sobre los tratamientos del cáncer de ovario y las terapias dirigidas a TNFR2.
El evento virtual contó con la participación de directivos de la empresa y del experto externo Dmitriy Zamarin. Martin Welschof, presidente y CEO, inauguró la sesión y presentó el programa, que abarcó el panorama actual de los tratamientos y los avances de la compañía.
Reportado por IA Imagen generada por IA Verificado por hechos
Researchers at McGill University report a drug-based method to temporarily enhance natural killer (NK) cells—an immune cell type—by inhibiting two proteins, improving the cells’ ability to attack several aggressive cancers in preclinical experiments.
Inovio Pharmaceuticals held its first-quarter 2026 earnings call on May 13 to discuss financial results for the period ended March 31 and provide updates on its DNA medicines platform.
Reportado por IA
Caribou Biosciences discussed progress on its off-the-shelf CAR-T therapies during a presentation at the Bank of America Global Healthcare Conference on May 13. Chief executive Rachel Haurwitz highlighted Phase I data for two programs that target lymphoma and multiple myeloma.
A new treatment called Daraxonrasib has shown strong results against advanced pancreatic cancer in a recent clinical trial. The drug targets a genetic mutation long considered impossible to treat effectively.
Reportado por IA
A protein called NFIL3 has been identified as a key factor in reducing the long-term performance of CAR T cells used in cancer treatment. Researchers showed that disabling this protein allows the engineered cells to remain active longer and fight tumors more effectively in laboratory models.